These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1246 related articles for article (PubMed ID: 18022071)
21. Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources. Vida VL; Gaitan G; Quezada E; Barnoya J; Castañeda AR Cardiol Young; 2007 Feb; 17(1):72-7. PubMed ID: 17184573 [TBL] [Abstract][Full Text] [Related]
22. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease? Madden BP; Sheth A; Wilde M; Ong YE Vascul Pharmacol; 2007; 47(2-3):184-8. PubMed ID: 17627899 [TBL] [Abstract][Full Text] [Related]
23. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Kothari SS; Duggal B Indian Heart J; 2002; 54(4):404-9. PubMed ID: 12462669 [TBL] [Abstract][Full Text] [Related]
24. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618 [TBL] [Abstract][Full Text] [Related]
25. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension. Diaz-Guzman E; Heresi GA; Dweik RA; Minai OA Respir Med; 2008 May; 102(5):681-9. PubMed ID: 18280130 [TBL] [Abstract][Full Text] [Related]
26. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Zhang ZN; Jiang X; Zhang R; Li XL; Wu BX; Zhao QH; Wang Y; Dai LZ; Pan L; Gomberg-Maitland M; Jing ZC Heart; 2011 Nov; 97(22):1876-81. PubMed ID: 21948962 [TBL] [Abstract][Full Text] [Related]
27. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Tay EL; Papaphylactou M; Diller GP; Alonso-Gonzalez R; Inuzuka R; Giannakoulas G; Harries C; Wort SJ; Swan L; Dimopoulos K; Gatzoulis MA Int J Cardiol; 2011 Jun; 149(3):372-6. PubMed ID: 20304507 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827 [TBL] [Abstract][Full Text] [Related]
31. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512 [TBL] [Abstract][Full Text] [Related]
32. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Lim ZS; Salmon AP; Vettukattil JJ; Veldtman GR Int J Cardiol; 2007 May; 118(2):178-82. PubMed ID: 17027100 [TBL] [Abstract][Full Text] [Related]
33. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Bharani A; Mathew V; Sahu A; Lunia B Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589 [TBL] [Abstract][Full Text] [Related]
34. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. Jacobs W; Boonstra A; Marcus JT; Postmus PE; Vonk-Noordegraaf A J Heart Lung Transplant; 2009 Mar; 28(3):280-4. PubMed ID: 19285621 [TBL] [Abstract][Full Text] [Related]
36. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333 [TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
38. Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. Wong RC; Koh GM; Choong PH; Yip WL Int J Cardiol; 2007 Jul; 119(3):400-2. PubMed ID: 17064789 [TBL] [Abstract][Full Text] [Related]
39. One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension. Samarzija M; Zuljević E; Jakopović M; Sever B; Knezević A; Dumija Z; Vidjak V; Samija M Coll Antropol; 2009 Sep; 33(3):799-803. PubMed ID: 19860106 [TBL] [Abstract][Full Text] [Related]
40. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use? Chapman TH; Wilde M; Sheth A; Madden BP Vascul Pharmacol; 2009; 51(2-3):90-5. PubMed ID: 19386283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]